Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication
The Oncologist · 06.09.2024 · 29 (9) · 806-810
DOI: 10.1093/oncolo/oyae158 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 26.06.2024. Verfasst von Kashyap Padmaraju und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Chicago Medical Center, Chicago, IL, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Premedication, Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Daratumumab-hyaluronidase-fihj (Dara-SQ) is frequently used in the treatment of plasma cell disorders and is associated with improved outcomes. Dara-SQ was shown to be non-inferior to intravenous daratumumab (Dara-IV) in efficacy, safety, and associated with fewer administration-related reactions (ARRs). Despite the lower ARR risk with Dara-SQ, package labeling still recommends indefinite premedication. In this study, we investigated the safety of premedication discontinuation after one cycle of Dara-SQ. Materials and Methods This pre-post interventional quality improvement study included all patients aged 18 years and older diagnosed with multiple myeloma or light chain (AL) amyloidosis who received at least one dose of Dara-SQ. Patients in Arm 1 received Dara-SQ per package labeling, while patients in Arm 2 had premedication omitted (excluding dexamethasone) after cycle 1. The primary endpoint was the incidence of ARR after cycle 1. Overall ARR rate and therapy time saved were also evaluated.
Results
A total of 102 patients (63 in Arm 1 and 39 in Arm 2) were included. There were zero reactions in either arm after cycle 1 across 1479 Dara-SQ doses administered over a 30-month period with or without premedication omission. The overall ARR rate was 2.9% (3/102), which all occurred prior to premedication omission. Therapy timed saved from premedication omission was 194 hours in a 6-month period, equating to approximately $140 000 USD.
Conclusion
ARRs to Dara-SQ were rare, mild, and occurred during cycle 1 prior to premedication omission. Omission of noncorticosteroid premedication is safe, feasible, and carries substantial time and cost savings for patients and infusion centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Chicago Medical Center, Chicago, IL, United States.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, United States.
ORCID-Profile: Kashyap Padmaraju
Zitieren
APA
Padmaraju, K., Kelly, K., Jakubowiak, A. J., & Derman, B. A. (2024). Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. The Oncologist, 29(9), 806-810. https://doi.org/10.1093/oncolo/oyae158
Vancouver
Padmaraju K, Kelly K, Jakubowiak AJ, Derman BA. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. The Oncologist. 2024;29(9):806-810. doi:10.1093/oncolo/oyae158
BibTeX
@article{Padmaraju2024,
author = {Padmaraju, Kashyap and Kelly, Kaitlin and Jakubowiak, Andrzej J and Derman, Benjamin A},
title = {Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {9},
pages = {806--810},
doi = {10.1093/oncolo/oyae158}
}
EUVIMED